Palogic Value Management L.P. Takes $2.26 Million Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Palogic Value Management L.P. purchased a new stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 320,000 shares of the company’s stock, valued at approximately $2,262,000. Palogic Value Management L.P. owned about 0.53% of Health Catalyst at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Quantbot Technologies LP purchased a new stake in shares of Health Catalyst during the 4th quarter valued at $29,000. Quest Partners LLC purchased a new stake in Health Catalyst during the third quarter worth about $34,000. Quadrature Capital Ltd bought a new stake in Health Catalyst in the third quarter worth about $84,000. Stoneridge Investment Partners LLC purchased a new position in Health Catalyst in the fourth quarter valued at about $77,000. Finally, Virtu Financial LLC purchased a new position in Health Catalyst in the fourth quarter valued at about $110,000. 85.00% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on HCAT. Piper Sandler lowered their price target on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 11th. Stifel Nicolaus lowered their target price on Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research note on Thursday, February 27th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a research note on Wednesday, January 8th. Citigroup decreased their price objective on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, January 10th. Finally, Stephens dropped their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $9.27.

Insider Transactions at Health Catalyst

In related news, General Counsel Benjamin Landry sold 13,827 shares of the business’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the transaction, the general counsel now directly owns 160,437 shares in the company, valued at $729,988.35. The trade was a 7.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Duncan Gallagher sold 4,500 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $6.93, for a total value of $31,185.00. Following the completion of the sale, the director now directly owns 69,938 shares in the company, valued at approximately $484,670.34. The trade was a 6.05 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,030 shares of company stock valued at $330,757. 2.50% of the stock is currently owned by company insiders.

Health Catalyst Stock Performance

Health Catalyst stock opened at $4.55 on Friday. Health Catalyst, Inc. has a 1-year low of $3.76 and a 1-year high of $9.24. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $319.46 million, a PE ratio of -3.37 and a beta of 1.41. The firm’s 50 day simple moving average is $5.03 and its 200 day simple moving average is $6.87.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.